Investor Presentation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation South San Francisco, CA -- May 21, 2019 -- Verily, an Alphabet company, today announced strategic alliances with Novartis (NYSE: NVS), Otsuka (NYSE: OTSKY), Pfizer Inc. (NYSE: PFE) and Sanofi (EURONEXT: SAN, NASDAQ: SNY) to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed to engage more patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of a clinic. Across the United States, the number of people participating in clinical research -- including clinical trials and observational studies -- is less than 10% of the population.1 In addition to low participation, challenges in research include data fragmentation, inefficient operations and limited value for patients. Alongside academic research institutions, patient-advocacy groups and health systems, Verily and its industry partners aim to implement a more patient-centric, technology-enabled approach to research, and increase the number and diversity of clinical research participants. They will also explore novel approaches to generating real-world evidence using the Baseline Platform to collect, organize and activate health information from electronic health records, sensors and other digital sources. Over the coming years, Novartis, Otsuka, Pfizer and Sanofi each plan to launch clinical studies leveraging the platform across diverse therapeutic areas, such as cardiovascular disease, oncology, mental health, dermatology and diabetes. -
Darpinstm the Next Generation of Protein Drugs MP0112 – the Best
Developing DARPin® therapies to improve health and advance modern medicine Corporate Presentation June 2015 Disclaimer NEITHER THIS DOCUMENT NOR ANY PART OR COPY OF IT NOR THE INFORMATION CONTAINED IN IT AND ANY RELATED MATERIALS MAY BE TAKEN OR TRANSMITTED INTO THE UNITED STATES OR DISTRIBUTED OR REDISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. -
Quarterly Review
Tropical Gastroenterology 2008.29;4:187–193 Quarterly Have hematopoietic growth factors made an Review impact on the management of liver disease? Pankaj Tyagi and Kaushal Madan ABSTRACT Department of Gastroenterology, It is clear that the major indication for the use of hematopoietic growth factors in hepatology GB Pant Hospital & Department of is to counteract the adverse effects of interferons (neutropenia and thrombocytopenia) and Medical Hepatology, ribavirin (hemolytic anaemia) during the treatment of hepatitis C infection. This is important Institute of Liver and Biliary Sciences, because the probability of SVR depends on proper adherence to therapy (at least 80% of the New Delhi requisite dose maintained for at least 80% of the requisite duration) and proper adherence can only be achieved if the side effects are reduced to a minimum. Even though the studies Correspondence: Dr. Kaushal Madan have demonstrated beyond doubt that the use of hematopoietic growth factors does indeed Email: [email protected] reduce the incidence and severity of these adverse effects and helps the patients to complete the course of therapy, the data on improvement of SVR is still limited. There is only one study of darbepoetin and filgrastim showing the beneficial effect on SVR. Even among the hematological side effects, possibly the only significant effect which limits the use of optimal HCV therapy is the hemolytic anaemia induced by ribavirin. The other two main side effects, i.e. neutropenia and thrombocytopenia are not clinically problematic. The use of such growth factors would be particularly effective if patients who have advanced liver disease or cirrhosis are able to receive adequate anti-viral therapy as has been demonstrated in the study of eltrombopag among HCV cirrhotics. -
WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/063180 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (74) Agent: WILLIAMS, Rachel; Novozymes Biopharma UK A61K 39/00 (2006.01) C07K 16/00 (2006.01) Ltd., Castle Court, 59 Castle Boulevard, Nottingham Not A61K 39/395 (2006.01) tinghamshire NG7 1FD (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2014/073261 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 29 October 2014 (29.10.2014) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 190750.3 29 October 2013 (29. 10.2013) EP SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 14166865.7 2 May 2014 (02.05.2014) EP TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: NOVOZYMES BIOPHARMA DK A S (84) Designated States (unless otherwise indicated, for every [DK/DK]; Krogshoejvej 36, DK-2880 Bagsvaerd (DK). -
312.1.Full.Pdf
Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1. -
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models. -
Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection
HCV Treatment Complications Volume 20 Issue 4 October/November 2012 Perspective Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection The addition of direct-acting antivirals (DAAs) to hepatitis C virus (HCV) Psychiatric Complications treatment regimens has made treatment more effective and patient Depression is the most common psy- management more complex. Shepherding patients through a full course of chiatric complication encountered in HCV therapy requires motivation and involvement on the part of the patient HCV patients, with mild to moderate and the physician. Indeed, physician inexperience and lack of confidence in depression found in as much as 80% of guiding patients through the challenges of treatment appears to be a primary patients. Bipolar disorder and schizo- reason for early discontinuation of therapy. Among the many complications phrenia are also not infrequently en- of HCV treatment that must be managed efficiently and effectively are countered. depression and other psychiatric disorders; hematologic abnormalities There is little evidence to support including DAA- and ribavirin-associated anemia and peginterferon alfa- a benefit of preemptive antidepres- associated neutropenia and thrombocytopenia; rash and drug eruptions, sant therapy in all patients undergo- including telaprevir-associated rash; and weight loss. Practical considerations ing HCV treatment, though a recent in management of these common complications are offered. This article randomized trial of HCV patients -
DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic) -
Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle
bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Targeting fibrosis in the Duchenne Muscular Dystrophy mice model: an uphill battle 2 Marine Theret1#, Marcela Low1#, Lucas Rempel1, Fang Fang Li1, Lin Wei Tung1, Osvaldo 3 Contreras3,4, Chih-Kai Chang1, Andrew Wu1, Hesham Soliman1,2, Fabio M.V. Rossi1 4 1School of Biomedical Engineering and the Biomedical Research Centre, Department of Medical 5 Genetics, 2222 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada 6 2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Minia 7 University, Minia, Egypt 8 3Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, 9 Darlinghurst, NSW, 2010, Australia 10 4Departamento de Biología Celular y Molecular and Center for Aging and Regeneration (CARE- 11 ChileUC), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 12 Santiago, Chile 13 # Denotes Co-first authorship 14 15 Keywords: drug screening, fibro/adipogenic progenitors, fibrosis, repair, skeletal muscle. 16 Correspondence to: 17 Marine Theret 18 School of Biomedical Engineering and the Biomedical Research Centre 19 University of British Columbia 20 2222 Health Sciences Mall, Vancouver, British Columbia 21 Tel: +1(604) 822 0441 fax: +1(604) 822 7815 22 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. -
Cenicriviroc CSF Abstract Page 1 of 3 Title: Cerebrospinal Fluid Exposure
Cenicriviroc CSF Abstract Title: Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment Authors: Jasmini Alagaratnam1, Laura Else2, Sujan Dilly Penchala2, Elizabeth Challenger2, Ken Legg1, Claire Petersen1, Brynmor Jones3, Ranjababu Kulasegaram4, Star Seyedkazemi5, Eric Lefebvre5, Saye Khoo2 and Alan Winston1 1. Division of Infectious Diseases, Department of Medicine, Imperial College London, London W2 1PG 2. Department of Pharmacology, University of Liverpool, Liverpool L69 7SX, UK 3. Department of Radiology, Imperial College Healthcare NHS Trust, London W2 1NY 4. St. Thomas’ Hospital, London W6 8RP, UK 5. Clinical Development, Allergan plc, South San Francisco, USA Page 1 of 3 Cenicriviroc CSF Abstract Abstract Background: Cenicriviroc, a dual C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonist, is a potential adjunctive therapy, along with antiretroviral therapy (ART), for the management of HIV-associated cognitive disorders. Materials and Methods: Virologically suppressed persons living with HIV (PLWH) with a clinical diagnosis of HIV-related cognitive impairment intensified ART with cenicriviroc once daily, dose dependent on current ART, for eight weeks. Subjects with current or previous use of CCR5 inhibitors were not eligible. We assessed cerebrospinal fluid (CSF) exposure of cenicriviroc and CSF albumin at week 8, and changes in cognitive function over 8 weeks. Cenicriviroc concentration was determined using reverse phase high-performance liquid chromatography (HPLC) with geometric mean (GM) and 95% confidence intervals (CI) calculated. The proposed cenicriviroc target concentration was above the 90% effective concentration (EC90) for cenicriviroc (0.17 ng/mL), with the lower limit of quantification (LLQ) 0.24 ng/mL taken as target concentration. -
CA Signed Novartis 315 Settlement Agreement Signed California
STATE SETTLEMENT AGREEMENT I. PARTIES This Settlement Agreement (the "Agreement") is entered into between the State of California ("the State") and Novartis Pharmaceuticals Corporation ("Novartis"), collectively, "the Parties." II. PREAMBLE As a preamble to this Agreement, the Parties agree to the following: A. At all relevant times, Novartis, (a subsidiary of Novartis International AG, which is headquartered in Basel, Switzerland) was a corporation with its principal place of business in East Hanover, New Jersey, distributed, marketed and/or sold pharmaceutical products in the United States, including drugs sold under the trade names of Lotrel, Valturna, Starlix, Tekamlo, Diovan, Diovan HCT, Tekturna, Tekturna HCT, Exforge, and Exforge HCT (the "Covered Drugs"). B. On January 5, 2011 , Oswald Bilotta, (the "Relater") filed a sealed qui tam action, which was subsequently amended on October 19, 2012, as of right on April 3, 2013 (pursuant to an unopposed motion dated March 21 , 2013), and on July 10, 2013 (pursuant to a stipulation dated July 8, 2013) (the "Civil Action") in the United States District Court for the Southern District of New York captioned United States of America et al. , ex rel. Oswald Bilotta et al. v. Novartis Pharmaceuticals Corporation Civil Action No. 1 l-cv-00071 , alleging, inter alia, that Novartis violated the False Claims Act ("FCA") and the Anti-Kickback Statute, 42 U.S.C. §I320a-7b(b) (the "AKS"), by paying doctors remuneration to prescribe the drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Diovan, Diovan HCT, Exforge, and Exforge HCT through the mechanism ofspeaker program honoraria and related misconduct. Novartis-315 Page 1 of 19 On April 26, 2013, the United States intervened in the Civil Action against Novartis by filing a Notice of Election to Intervene and Complaint-in-Intervention, in which it is asserted that claims against Novartis under the FCA and common law. -
Novartis R&D and Investor Update
Novartis AG Investor Relations Novartis R&D and investor update November 5, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” “agreement to acquire,” or similar expressions, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this presentation, or regarding potential future revenues from such products, or regarding the proposed acquisition of Endocyte, Inc. (Endocyte) by Novartis including the potential outcome and expected timing for completion of the proposed acquisition, and the potential impact on Novartis of the proposed acquisition, including express or implied discussions regarding potential future sales or earnings of Novartis, and any potential strategic benefits, synergies or opportunities expected as a result of the proposed acquisition. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this presentation will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future.